Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study

Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study

Jean-Marie Rakic,1 Anita Leys,2 Heidi Brié,3 Kris Denhaerynck,4 Christy Pacheco,4 Stefaan Vancayzeele,3 Christine Hermans,3 Karen MacDonald,4 Ivo Abraham4,5 1Department of Ophthalmology, Centre Hospitalier Universitaire de Liège, Site du Sart Tilman, Liège, Belgium;...

Full description

Bibliographic Details
Main Authors: Rakic JM, Leys A, Brié H, Denhaerynck K, Pacheco C, Vancayzeele S, Hermans C, MacDonald K, Abraham I
Format: Article
Language:English
Published: Dove Medical Press 2013-09-01
Series:Clinical Ophthalmology
Online Access:http://www.dovepress.com/real-world-variability-in-ranibizumab-treatment-and-associated-clinica-a14404

Internet

http://www.dovepress.com/real-world-variability-in-ranibizumab-treatment-and-associated-clinica-a14404

Similar Items